Hemostemix Inc. provided update on CLI clinical trial. The company announced that ACP-01 has been used to treat over 300 patients, including on a compassionate basis and to no-option heart disease patients. The current CLI trial size remains at 95 patients. The Company anticipates that it will conduct a futility analysis for potentially stopping enrolment in the clinical trial when 42 subjects have completed at least 26 weeks of follow-up.